Opioid Based Articles & Analysis
2 news found
Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of financing. Funding will support the company through pre-clinical and GMP manufacturing scale up for its proprietary ketamine formulation, BB106, and the development of a wearable ...
Current off-label prescription of opioids, a leading agitator of overdose deaths and addiction, is the model of treatment. ...